Perner, Florian http://orcid.org/0000-0003-1010-3321
Schnoeder, Tina M.
Xiong, Yijun http://orcid.org/0000-0001-6348-9649
Jayavelu, Ashok Kumar
Mashamba, Nomusa
Santamaria, Nuria Tubio
Huber, Nicolas
Todorova, Kristina
Hatton, Charles http://orcid.org/0000-0001-9903-4291
Perner, Birgit
Eifert, Theresa
Murphy, Ciara
Hartmann, Maximilian
Hoell, Jessica I.
Schröder, Nicolas
Brandt, Sabine
Hochhaus, Andreas
Mertens, Peter R.
Mann, Matthias
Armstrong, Scott A. http://orcid.org/0000-0002-9099-4728
Mandinova, Anna
Heidel, Florian H. http://orcid.org/0000-0003-2438-1955
Article History
Received: 22 April 2021
Revised: 16 August 2021
Accepted: 18 August 2021
First Online: 31 August 2021
Competing interests
: SAA has been a consultant and/or shareholder for Epizyme Inc, Vitae/Allergan Pharmaceuticals, Imago Biosciences, Cyteir Therapeutics, C4 Therapeutics, OxStem Oncology, Accent Therapeutics, Neomorph Inc, and Mana Therapeutics. SAA has received research support from Janssen, Novartis, and AstraZeneca. All other authors have no competing financial interests to declare.